REGN Stock Drop: Regeneron Clinical Trials Lead to 9% Stock Drop and Securities Fraud Class Action for Investors
Bleichmar Fonti & Auld LLP announced a class action lawsuit against Regeneron Pharmaceuticals, alleging securities fraud related to the company's Phase III Fianlimab-Libtayo clinical trial. The complaint claims Regeneron misled investors regarding the trial's success, which allegedly contributed to stock drops of 6.2% and 9.8% in late April and mid-May 2026.
Key figures
- Drug Name
- Fianlimab-Libtayo
- Phase Of Trial
- Phase III
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.